Pacira BioSciences, Inc. Common Stock
PCRXPacira BioSciences, Inc. is a pharmaceutical company specializing in non-opioid, local analgesic products. It is best known for its flagship product, EXPAREL, a long-lasting local anesthetic used for postoperative pain management. The company focuses on developing and commercializing non-opioid pain control options to reduce reliance on opioids and improve patient recovery outcomes.
Company News
Pacira BioSciences granted inducement equity awards to ten new employees on July 2, 2026, consisting of stock options for 9,200 shares and restricted stock units for 18,200 shares. The awards were approved by the People & Compensation Committee under Nasdaq Listing Rule 5635(c)(4) without stockholder approval.
The osteoarthritis market is projected to grow at a 3% CAGR from 2026 to 2036, reaching USD 32.5 billion in 2025 across seven major markets. Growth is driven by an aging population, rising disease prevalence, and the launch of emerging therapies including LEVI-04, ZILOSUL, TissueGene-C, and AMZ001. Current treatment is dominated by opioids, but n...
Pacira BioSciences announced inducement equity awards to ten new employees on May 4, 2026, including stock options for 36,800 shares and restricted stock units for 27,700 shares. The awards were granted under the company's Amended and Restated 2014 Inducement Plan with an exercise price of $24.69 per share.
Pacira BioSciences CFO Shawn Cross exercised and sold 12,941 shares for approximately $326,000 on April 23, 2026, representing 10.94% of his direct holdings. The transaction was part of a pre-planned Rule 10b5-1 trading plan. Despite the insider sale, the company reported strong Q1 2026 results with $177 million in revenue (5% YoY growth) and bea...
Pacira BioSciences presented real-world data demonstrating that EXPAREL (bupivacaine liposome injectable suspension) is associated with lower total healthcare costs and reduced opioid utilization in outpatient total hip and knee arthroplasty procedures. Three studies showed cost savings ranging from $7,332 to $13,022 over 6 months post-surgery, w...
